Pharmaceutical Executive - Pharmaceutical news and analysis. Pharma management, sales, marketing & finance

ADVERTISEMENT

Previous Story Play / Pause Next Story
New & Noteworthy
2015 Pipeline Report: Burning Bright
The science of drug discovery is back on script—and the stars are cued up for a new generation of breakthrough therapies. But is pharma ready to raise its game and cut a deal with all those "prove it to me" payers?
Health 2.0 2014: Infrastructure Gets Sexy, HCP Apps Steal the Show
Two of the industry's most influential conferences occurred within weeks of each other this autumn – TEDMED and Health 2.0. Bill Drummy reviews both events.
Medicare Part B Data: Approach with Care
CMS's Part B data release has increased transparency but has also resulted in potentially misplaced scrutiny of high-billing doctors. Ben Scher, Kathleen Twigg, and Andrew Huson take a closer look.

Latest Pharm Exec Videos

Events
FDA/CMS Summit for Payers
December 11, 2014 - December 12, 2014
Washington, DC USA

10th Annual Summit on Biosimilars
January 29, 2015 - January 30, 2015
Alexandria, VA USA

Medicaid and Government Pricing Congress
June 3, 2015 - June 5, 2015
Lake Buena Vista, FL USA

13th Annual Product Complaints Congress for Life Sciences
June 23, 2015 - June 25, 2015
Washington, DC USA

PAAS 2015 – Patient Adherence and Access Summit
June 23, 2015 - June 24, 2015
Philadelphia, PA USA

CytRx Faces Partial Clinical Hold after Death in Compassionate Use Program
FDA "Stymies Competition in Drug Industry", Says PCMA
EMA Revises Conflict-of-Interest Policy
How Gilead Blew Out the Lights With Sovaldi
Pharma Showing Signs of Stability Despite Patent Cliffs
Tufts Pegs Drug Development Cost at $2.6 billion  MSF Cries Foul
Healthcare Reform Tom NortonPulling Back the Curtains on Obamacare Rx Usage
Europe Peter O'DonnellWho's in Charge of Medicines in Brussels?
Healthcare Reform Casey McDonaldSparks Fly at Prix Galien Healthcare Reform Forum
Open Payments Jill Wechsler"Sunshine" Continues to Exempt CME Funding
 More
Survey
Which of the following activities is your most important upcoming initiative?
Domestic M&A
Cross-border M&A
New strategic alliance or joint venture
End an existing strategic alliance or joint venture
Outsource a business process or function
Domestic M&A
29%
Cross-border M&A
0%
New strategic alliance or joint venture
14%
End an existing strategic alliance or joint venture
0%
Outsource a business process or function
57%
View Results
PHARM EXEC GLOBAL DIGEST
Pharmaceutical Executive Digest EuropeTo read the latest issue of Pharm Exec Global Digest
Click here. Click here to receive the Digest into your inbox every month.
Click here